Gossamer Bio (NASDAQ:GOSS) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research note released on Friday morning, Benzinga reports. The brokerage currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Gossamer Bio’s Q3 2024 earnings at ($0.12) EPS, Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.00 EPS and FY2028 earnings at $0.29 EPS.

Other analysts have also recently issued research reports about the stock. Wedbush reissued an outperform rating and issued a $4.00 price target on shares of Gossamer Bio in a research note on Tuesday, August 13th. Oppenheimer began coverage on shares of Gossamer Bio in a research report on Tuesday, June 25th. They set an outperform rating and a $9.00 price objective for the company. Finally, The Goldman Sachs Group reaffirmed a buy rating and set a $8.00 price objective on shares of Gossamer Bio in a research report on Monday, June 17th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of Buy and an average price target of $9.20.

Gossamer Bio Stock Performance

Gossamer Bio stock opened at $0.88 on Friday. The firm has a 50 day simple moving average of $0.97 and a 200-day simple moving average of $0.94. Gossamer Bio has a 1-year low of $0.45 and a 1-year high of $1.60. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.21 and a quick ratio of 8.21. The stock has a market cap of $198.58 million, a price-to-earnings ratio of -0.83 and a beta of 1.93.

Insider Buying and Selling at Gossamer Bio

In other Gossamer Bio news, CEO Faheem Hasnain purchased 372,000 shares of the firm’s stock in a transaction on Friday, June 21st. The stock was bought at an average price of $0.67 per share, with a total value of $249,240.00. Following the transaction, the chief executive officer now directly owns 5,408,073 shares of the company’s stock, valued at approximately $3,623,408.91. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gossamer Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sivia Capital Partners LLC acquired a new stake in shares of Gossamer Bio in the 1st quarter valued at $29,000. SG Americas Securities LLC acquired a new stake in shares of Gossamer Bio in the 1st quarter valued at $34,000. Choreo LLC acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at $46,000. Algert Global LLC acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at $75,000. Finally, Sequoia Financial Advisors LLC raised its holdings in shares of Gossamer Bio by 27.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after purchasing an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.